Biogen, a major biotechnology company, took a 29 percent nosedive after stopping a trial for an Alzheimer's drug. Other health care stocks also fell.
News
- Stocks move broadly higher, led by technology companies
- Will more genetically engineered foods be approved under the FDA's new leadership?
The plan includes public webinars on animal genome editing, as well as guidance on plant and animal biotechnology. Given the current scientific ...
- Edwards proposing $19M more for Louisiana higher education
Other dollars would pay for LSU's Pennington Biomedical Research Center to recruit faculty, an expense matched with private foundation money.
- A case against a moratorium on germline gene editing
As a biomedical ethicist, I believe the objectors raise valid concerns about the relevance and usefulness of a moratorium that are worth reflecting upon ...
- Regulators just approved a new depression drug with the potential to be a game-changer (SAGE)
The US Food and Drug Administration on Tuesday approved an injection branded Zulresso that is made by biotech company Sage Therapeutics.